BP28920 Phase I study of RO6895882 in solid tumours
Research type
Research Study
Full title
AN OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION, PHASE I STUDY WITH AN EXPANSION PHASE, TO EVALUATE SAFETY, PHARMACOKINETICS AND THERAPEUTIC ACTIVITY OF RO6895882, AN IMMUNOCYTOKINE, CONSISTING OF A VARIANT OF INTERLEUKIN-2 (IL-2v) TARGETING CARCINOEMBRYONIC ANTIGEN (CEA) ADMINISTERED INTRAVENOUSLY, IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMOURS.
IRAS ID
145143
Contact name
Mark Middleton
Contact email
Sponsor organisation
F Hoffmann-La Roche Ltd
Eudract number
2013-003041-41
Clinicaltrials.gov Identifier
REC name
South Central - Oxford C Research Ethics Committee
REC reference
14/SC/0134
Date of REC Opinion
2 Apr 2014
REC opinion
Favourable Opinion